Disulfide-rich cyclic peptides found in nature offer exceptionally stable scaffolds that can be engineered to carry therapeutic payloads, potentially addressing drug targets that conventional medicines cannot reach.
Exceptional stabilityCyclic disulfide-rich peptides resist thermal, chemical, and enzymatic degradation — properties that most linear peptides lack, making them attractive drug scaffolds
What the researchers found
The review describes how disulfide-rich head-to-tail cyclic peptides possess exceptional thermal, chemical, and enzymatic stability due to their highly constrained structures. These naturally occurring peptide scaffolds can be utilized in two key ways for drug design:
1. Epitope grafting — inserting pharmaceutically active sequences into the stable cyclic framework to give them enhanced stability and bioavailability
2. Engineering — modifying the scaffold itself to increase selectivity and bioactivity for specific targets
These approaches open possibilities for addressing 'difficult' pharmaceutical targets that are not easily druggable by conventional small molecules or antibodies, including intracellular protein-protein interactions.
Why it matters
A major challenge in drug development is that many disease-causing proteins are considered 'undruggable' because small molecule drugs are too simple to bind them effectively, while antibodies are too large to reach intracellular targets. Cyclic disulfide-rich peptides bridge this gap — they are large and structured enough to bind complex protein surfaces, yet small and stable enough to potentially survive oral delivery and enter cells. This review outlines a roadmap for using nature's own molecular engineering to solve this problem.
How the study worked
This is a review article surveying current trends in peptide-based pharmaceuticals, with a focus on naturally occurring cyclic disulfide-rich peptide scaffolds. The authors describe the structural and pharmaceutical properties of these scaffolds and review grafting and engineering strategies used to create drug candidates.
What this study cannot tell us
As a review from 2014, it captures the state of the field at that time and may not reflect more recent advances in cyclic peptide synthesis, delivery, and clinical development. The review focuses on the theoretical promise of these scaffolds, and the abstract does not detail specific clinical successes or failures. The actual translation of grafted cyclic peptides into approved drugs remains an ongoing challenge. Oral bioavailability and cell permeability, while theoretically improved, have been difficult to achieve consistently in practice.
How to read the evidence
This is a review article that synthesizes existing research rather than presenting new experimental data. It provides a conceptual framework and survey of the field but does not contribute original evidence. The underlying studies vary in their evidence levels from in vitro to early preclinical.
When this study was published
Published in 2014, this review captured the field at an inflection point when cyclic peptide drug design was gaining mainstream pharmaceutical attention. The concepts described remain foundational, though the field has advanced significantly in subsequent years with new synthesis methods and clinical candidates.
The bigger picture
This review comes from David Craik's laboratory, one of the pioneering groups in cyclotide (cyclic peptide) research. The concept of using stable natural peptide frameworks as drug scaffolds has grown into a major branch of pharmaceutical research, influencing companies developing cyclic peptide therapeutics for cancer, pain, cardiovascular disease, and infectious disease. The approach represents a middle ground between traditional small molecule drugs and large biologics, potentially combining the best properties of both.
Questions still open
- Have any disulfide-rich cyclic peptide drug candidates advanced to clinical trials since this review was published?
- Can cyclic peptide scaffolds be engineered for oral bioavailability, or do they still primarily require injection?
- How do cyclic peptide therapeutics compare to other emerging modalities like stapled peptides and macrocyclic drugs in terms of druggability?
Common questions
What makes cyclic disulfide-rich peptides so stable compared to regular peptides?
What does it mean to 'graft' a drug sequence onto a peptide scaffold?
Read the original research
Disulfide-rich macrocyclic peptides as templates in drug design.
European journal of medicinal chemistry, 77, 248-57
Citation
Northfield, Susan E; Wang, Conan K; Schroeder, Christina I; Durek, Thomas; Kan, Meng-Wei; Swedberg, Joakim E; Craik, David J. (2014). Disulfide-rich macrocyclic peptides as templates in drug design.. European journal of medicinal chemistry, 77, 248-57. https://doi.org/10.1016/j.ejmech.2014.03.011